Sign inJoin waitlistJoin the waitlist

Patrick Boland

Associate Program Director, GI Medical Oncology · Rutgers Health

Credentials: · · · · · ·

History

GI Medical Oncology · Rutgers Health
Present
Rutgers Health
Present
University at Buffalo School of Medicine
Present

Fox Chase Cancer Center
2009–2011
Internal Medicine
Boston University Medical Center
2006–2009
Sidney Kimmel Medical College at Thomas Jefferson University
2002–2006

Research

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164
Journal of Clinical Oncology · 2020 · 801 citations
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper
Review · Nature Reviews Clinical Oncology · 2020 · 305 citations
Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study
The Lancet Oncology · 2019 · 234 citations

CF
Christos Fountzilas
9 papers · 1 as a fellow
Howard Hochster
9 papers
Renuka Iyer
8 papers
Steven Nurkin
8 papers
Tanios Bekaii-Saab
7 papers
Wen Ma
7 papers
Emmanuel Gabriel
6 papers · 5 as a fellow
Sarbajit Mukherjee
6 papers
Heinz-Josef Lenz
5 papers
MF
Marwan Fakih
5 papers
Russell Langan
5 papers
Brett Ecker
4 papers

Clinical trials

sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)
Principal investigator · Recruiting · Phase 2
Rutgers, The State University of New Jersey
2022–2027
Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer
Principal investigator · Suspended · Phase 2
Rutgers, The State University of New Jersey
2022–2028
A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC
Principal investigator · Terminated · Phase 2
Patrick Boland
2018–2024
Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment
Principal investigator · Withdrawn · Phase 2
Roswell Park Cancer Institute
2015